Pharmacy Law Lowdown: FDA’s Evaluation of Peptides

What happened at the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting over the summer was not a green light for peptide compounding but the clearest signal yet that the regulatory framework governing these substances is expected to shift significantly.

In the September rendition of Pharmacy Law Lowdown, hosts Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, from Buchanan Ingersoll & Rooney, joined Drug Topics® live to assess the fallout of the FDA committee’s July 23 and 24 hearing. In their detailed discussion of everything pharmacists need to know about peptides in the marketplace, Morgan and Lee touched on the meeting itself, what PCAC’s functions are, issues with gray market proliferation, and so much more.

“There's so much demand in the market, without the proper guardrails and regulations. You have a phone; you could just go online right now and then buy a peptide from a gray market,” said Lee. “I thought the conversation [at the meeting] was going to be heavily about clinical safety and efficacy…but a lot of discussion was around policy on whether these peptides should be recommended or added to the bulk list because of the gray market.”

READ MORE: The Legislation Setting the Stage for Pharmacy’s Next Leap

Understanding Category Reclassification and Legal Realities

In explaining the regulatory mechanisms, Lee noted that the core debate centered on moving 7 unapproved bulk peptides from Category 2, which includes substances deemed unsafe for human compounding, to Category 1, which lists substances eligible for 503A compounding.

For state-licensed 503A compounding pharmacies, drugs can legally be compounded only if they possess an official United States Pharmacopeia monograph, form a component of an FDA-approved drug, or appear on the 503A bulk drug substances list. None of the 7 peptides evaluated, including BPC-157, TB-500, KPV, MOTS-c, epitalon, semax, and emideltide, meet these statutory criteria.^1,2

Despite FDA scientific staff urging against inclusion due to missing quality monographs and characterization gaps, the advisory panel voted to recommend 6 of the 7 peptides for the bulk list. However, Lee emphasized that the advisory vote does not grant immediate legal authority to compounders.

Until the FDA completes formal administrative rulemaking, compounding these substances remains technically unlawful under federal standards.²

Scientific Concerns vs Market Harm Reduction

The regulatory friction highlights a deeper divide between clinical caution and public demand.^2-4

Peptides are short-chain amino acids that act as cellular signaling messengers, with over 100 approved therapies, like insulin, already in clinical practice. However, unapproved wellness peptides sold online often lack human clinical trials, creating risks of immunogenicity, injection site irritation, and unknown long-term side effects.^1,2,4,5

Medical experts from the American Medical Association and sports medicine specialists emphasize that patient enthusiasm frequently outpaces rigorous scientific evidence.^4,5

Opponents of immediate listing, including the American Pharmacists Association and the Institute for Safe Medication Practices, warn that bypassing traditional trial standards could expose patients to unvetted formulations without established safety profiles.^3,4

Conversely, proponents argue that bringing peptide manufacturing into state-licensed 503A pharmacies or FDA-regulated 503B outsourcing facilities creates essential guardrails against an unchecked gray market filled with contaminated raw product.³

What Lies Ahead for Compounding Pharmacies

Looking forward, pharmacy professionals face a complex transition period as the FDA considers notice and comment rulemaking. Although public interest has grown following comments from Health and Human Services Secretary Robert F. Kennedy Jr., formal regulatory changes typically require months or even years to enact.^2,3

During the interim phase, state boards of pharmacy will maintain primary oversight over 503A facilities, while 503B outsourcing facilities remain under direct federal inspection. Pharmacists must navigate patient inquiries carefully, balancing clinical safety against the commercial availability of gray market alternatives.³

Morgan and Lee advise practitioners to stay informed on federal rulemaking dockets, adhere strictly to USP standards, and maintain rigorous supply chain traceability that protects patient safety as the regulatory landscape evolves.² Check out their insights in this month’s episode.

Be sure to tune into Drug Topics for important updates in pharmacy law and how to handle them from hosts Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, shareholders at Buchanan Ingersoll & Rooney, a national law firm that provides legal, business, regulatory, and government relations advice to a wide range of clients. All episodes of Pharmacy Law Lowdown will be available in video format via Drug Topics in the latter half of each month. Check out our most recent episode here: Pharmacy Law Lowdown: CVS Caremark’s Settlement with FTC.

REFERENCES

1. Gallagher A. FDA panel to evaluate 7 popular peptides for compounding substances list. Drug Topics. July 6, 2026. Accessed September 24, 2026. https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list

2. DiSabatino DP, Mercer A. Compounded peptides on the loose: what the recent PCAC meeting means for industry. August 7, 2026. Accessed September 24, 2026. https://www.sheppard.com/insights/blogs/compounded-peptides-on-the-loose-what-the-recent-pcac-meeting-means-for-industry

3. Nowosielski B. FDA votes in favor of peptides after lengthy deliberation. Drug Topics. July 24, 2026. Accessed September 24, 2026. https://www.drugtopics.com/view/fda-votes-in-favor-of-peptides-after-lengthy-deliberation

4. Stone W. What's behind the push to make peptide therapies more readily available. NPR. July 8, 2026. Accessed September 24, 2026. https://www.npr.org/2026/07/08/nx-s1-5885073/fda-peptides-compounding-pharmacies

5. Peptides: breakthrough solution or risky trend? AMA. August 19, 2026. Accessed September 24, 2026. https://www.ama-assn.org/public-health/prevention-wellness/peptides-breakthrough-solution-or-risky-trend